Accès ouvert déclaré
2022
article
Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022
Nathaniel M. Lewis, Nancy L. Murray, Katherine Adams, Diya Surie, Manjusha Gaglani, Adit A. Ginde, Tresa McNeal, Shekhar Ghamande, David J. Douin, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Nathan I. Shapiro, Kevin W. Gibbs, D. Clark Files, David N. Hager, Harith Ali, Matthew E. Prekker, Anne Frosch, Matthew C. Exline, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Arnold S. Monto, Adam S. Lauring, Catherine L. Hough, Laurence W. Busse, William Bender, Abhijit Duggal, Jennifer G. Wilson, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Hilary M. Babcock, Jennie H. Kwon, James D. Chappell, Natasha Halasa, Carlos G. Grijalva, Todd W. Rice, Adrienne Baughman, Christopher J. Lindsell, Kimberly W. Hart, Jillian P. Rhoads, Meredith McMorrow, Mark W. Tenforde, Wesley H. Self, Manish M. Patel, Nicole Calhoun, Kempapura Murthy, Judy Herrick, Amanda McKillop, Eric Hoffman, Martha Zayed, Michael Smith, Lori-Ann Kozikowski, Lesley De Souza, Scott Ouellette, Michael Bolstad, Brianna Coviello, Robert A. Ciottone, Arnaldo deVilla, Ana Grafals, Conor Higgins, Carlo Ottanelli, Kimberly Redman, Douglas Scaffidi, Alexander Weingart, Samantha M. Olson, Meagan Stephenson, Maraia Tremarelli, Caitlin Turbyfill, Omar Mehkri, Megan Mitchell, Zachary Griffith, Connery Brennan, Kiran Ashok, Bryan Poynter, Caitlin ten Lohuis, Nicholas Stanley, Sophia Zhang, Heidi L. Erickson, Audrey Hendrickson, Sean Caspers, Walker Tordsen, Olivia Kaus, Tyler Scharber, Jenna Lumpkin, Cassie Smith, Hunter Marshall, N David, Arber Shehu, Richard E. Rothman, Rahul Nair, Jen-Ting Chen, Sarah Karow, Maryiam Khan, Preston So, Madison So, Elizabeth Schwartz, Mena Botros, Hae‐Un Jung, Jesus Martinez, Andrea Luong, Bao Huynh, Habiba Ibrahim, Cynthia Villanueva-Vargas, Juliana Villanueva-Vargas, Suha Quadri, Cynthia M. Pérez, Trevor Frankel, Omai B. Garner, Sukantha Chandrasekaran, David Huynh, Aimee Steinwand, Cori Withers, Conner Driver, S. Paul Wright, Paul Nassar, Shannon R. Landers, Karin Nielsen, Noble Briggs, Cathy Fairfield, Chris Mallow, Hayley B. Gershengorn, EJ McSpadden, Rachel Truscon, Anne Kaniclides, Lara Thomas, Ramsay Bielak, Weronika Damek Valvano, Rebecca Fong, William J. Fitzsimmons, Christopher Blair, Julie Gilbert, Leigh Baker, Christine D Crider, Kyle A Steinbock, Thomas C Paulsen, Layla A. Anderson, Ian Jones, Kelsey N. Womack, Christy Kampe, Jakea Johnson, Jake Sturgill, Kim Hart, R. Trigg McClellan, Yuwei Zhu, Laura Short, Lauren J Ezzell, Margaret E Whitsett, Rendie McHenry, Samarian J Hargrave, Marcia Blair, Jennifer L Luther, Claudia Guevara Pulido, Bryan P M Peterson, Mary LaRose, Leigha Landreth, Madeline Hicks, Lisa Parks, Jahnavi Bongu, David W. McDonald, Candice Cass, Sondra Seiler, David Park, Tiffany Hink, Meghan A. Wallace, Carey‐Ann D. Burnham, Olivia Arter
13Citations signalées, ce qui n’est pas une note de qualité
26Institutions déclarées
1Pays d’affiliation déclarés
Rattachement africain : us.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) studies are increasingly reporting relative VE (rVE) comparing a primary series plus booster doses with a primary series only. Interpretation of rVE differs from traditional studies measuring absolute VE (aVE) of a vaccine regimen against an unvaccinated referent group. We estimated aVE and rVE against COVID-19 hospitalization in primary-series plus first-booster recipients of COVID-19 vaccines. Methods: Booster-eligible immunocompetent adults hospitalized at 21 medical centers in the United States during December 25, 2021-April 4, 2022 were included. In a test-negative design, logistic regression with case status as the outcome and completion of primary vaccine series or primary series plus 1 booster dose as the predictors, adjusted for potential confounders, were used to estimate aVE and rVE. Results: A total of 2060 patients were analyzed, including 1104 COVID-19 cases and 956 controls. Relative VE against COVID-19 hospitalization in boosted mRNA vaccine recipients versus primary series only was 66% (95% confidence interval [CI], 55%-74%); aVE was 81% (95% CI, 75%-86%) for boosted versus 46% (95% CI, 30%-58%) for primary. For boosted Janssen vaccine recipients versus primary series, rVE was 49% (95% CI, -9% to 76%); aVE was 62% (95% CI, 33%-79%) for boosted versus 36% (95% CI, -4% to 60%) for primary. Conclusions: Vaccine booster doses increased protection against COVID-19 hospitalization compared with a primary series. Comparing rVE measures across studies can lead to flawed interpretations of the added value of a new vaccination regimen, whereas difference in aVE, when available, may be a more useful metric.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021–April 2022
- Date Crossref
- 31/12/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyImmune responses and vaccinations